RCS - Ondine Biomedical - Steriwave in Half of Fraser Health Hospitals

Ondine BiomedicalAnnouncement

08/07/2025 10:30

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250708:nRSH1867Qa&default-theme=true

RNS Number : 1867Q  Ondine Biomedical Inc.  08 July 2025

8 July 2025

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Steriwave in Half of Fraser Health Hospitals

Ridge Meadows and Chilliwack General Hospitals to Deploy Steriwave(®) Nasal
Photodisinfection for Pre-Surgical Decolonization

Ondine Biomedical Inc. (AIM: OBI) is pleased to announce that Ridge Meadows
Hospital and Chilliwack General Hospital, both part of the Fraser Health
Authority in British Columbia, are adopting Steriwave(®) nasal
photodisinfection as a standard of care for pre-surgical nasal decolonization
for orthopedic surgery patients. undergoing surgery. The adoption of Steriwave
is a strategic response to the growing threat of antibiotic resistance in
healthcare and the significant burden surgical site infections (SSIs) place on
patients and the healthcare system.

Fraser Health is the largest of British Columbia's five regional health
authorities, responsible for delivering care to over one-third of the
province's population. With these latest hospital adoptions, Steriwave is in
half of Fraser Health's hospitals performing major surgeries, reinforcing the
growing momentum behind nasal photodisinfection across Canada's public health
system.

Surgical site infections (SSIs) following major surgeries remain a serious
concern, with approximately 3%  mortality [ 1 ], extended hospital stays
averaging nearly 10 days [ 2 ], s. A comprehensive Alberta study found that
complex SSIs after hip and knee surgeries can cost hospitals up to CA$95,000
per case and carry significant risks for patients.[ 3 ] The patient's own nose
is a major source of hospital infections. Approximately 69% of SSIs are caused
by pathogens colonizing the nasal passages.[ 4  5  (#_edn5) - 6 ] Leading
health authorities-including the CDC (Centers for Disease Control and
Prevention), WHO (World Health Organisation), and SHEA (Society for Healthcare
Epidemiology of America)-recommend nasal decolonization before major surgeries
to reduce SSI risk.

Unlike topical nasal antibiotics such as mupirocin-which are increasingly
limited by rising resistance and require multi-day patient adherence-Steriwave
is a five-minute, light-activated antimicrobial therapy that destroys harmful
nasal pathogens, including drug-resistant strains, without fostering
resistance or relying on patient compliance. Steriwave has demonstrated more
than 50% reduction in SSI rates, significantly improving patient outcomes and
reducing hospital readmissions.

Carolyn Cross, CEO of Ondine, commented:

"We are proud to support Ridge Meadows Hospital and Chilliwack General
Hospital-two respected centres of care within the Fraser Health Authority-as
they take this important step forward in advancing surgical safety. Their
adoption of Steriwave reflects a strong, proactive commitment to reducing
surgical site infections and limiting the spread of antibiotic resistance. We
commend their clinical leadership and dedication to innovation, and we look
forward to working closely with their teams to enhance infection prevention."

Steriwave nasal photodisinfection involves applying a proprietary
photosensitive agent to each nostril, followed by illumination with a specific
wavelength of red light. This process destroys bacteria, viruses, and fungi in
the nasal cavity immediately and without generating resistance, making it a
powerful tool in the fight against healthcare-associated infections.

 

Enquiries:

 Ondine Biomedical Inc.                                      www.ondinebio.com
 Carolyn Cross, CEO                                          +1 604 669 0555

or via Vane Percy & Roberts

 Strand Hanson Limited (Nominated & Financial Adviser)
 James Harris, Richard Johnson                               +44 (0)20 7409 3494

 Peel Hunt LLP (Broker & Joint Financial Advisor)
 James Steel, Dr. Chris Golden                               +44 (0)20 7418 8900

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy                                            +44 (0)77 1000 5910

 

 

 

About Ondine Biomedical Inc.

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies ('photodisinfection') for the
prevention and treatment of infections, including those caused by
multidrug-resistant organisms. Ondine has a pipeline of investigational
products, based on its proprietary photodisinfection technology, in various
stages of development.

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada, Australia, Mexico and several other countries under the
name Steriwave(®). In the US, it has been granted Qualified Infectious
Disease Product designation and Fast Track status by the FDA and is currently
undergoing clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

(#_ednref1) [ 1 ] Umscheid CA, et al. Estimating the proportion of
healthcare-associated infections that are reasonably preventable and the
related mortality and costs. Infection Control & Hospital Epidemiology,
2011;32(2):101-114. (link (https://doi.org/10.1086/657912) )

(#_ednref2) [ 2 ] Anderson DJ, et al. Strategies to Prevent Surgical Site
Infections in Acute Care Hospitals: 2014 Update. Infect. Control. Hosp.
Epidemiol. 2014;35:605-627. (link
(https://pmc.ncbi.nlm.nih.gov/articles/PMC4267723/) )

(#_ednref3) [ 3 ] Rennert-May ED, Conly J, Smith S, et al. The cost of
managing complex surgical site infections following primary hip and knee
arthroplasty: A population-based cohort study in Alberta, Canada. Infect
Control Hosp Epidemiol. 2018;39(10):1183-1188. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/abs/cost-of-managing-complex-surgical-site-infections-following-primary-hip-and-knee-arthroplasty-a-populationbased-cohort-study-in-alberta-canada/D1039C9F16AC6FE965C960D6C2494201)
)

(#_ednref4) [ 4 ] CDC. HAI Pathogens and Antimicrob Resist Report, 2018-2021.
(link (https://www.cdc.gov/nhsn/hai-report/index.html) )

(#_ednref5) [ 5 ] Nature. 2012;486:207-214. (link
(https://www.nature.com/articles/nature11234) )

(#_ednref6) [ 6 ] Biomedicines. 2022 Dec 26;11(1):54. (link
(https://www.mdpi.com/2227-9059/11/1/54/review_report) )

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUWAKRVWUBRRR